Presenter
Evelyn Yehudit Bischof
Prof. Evelyne Bischof, MD, MPH, FEFIM spent over a decade practicing medicine, while also lecturing at medical schools and performing clinical and translational research in Boston, New York, Shanghai and Basel, with extensive experience in scientific research and clinical practice at the following well-known and highly reputable institutions: University Hospital of Basel, Fudan Cancer Institute and Hospital; Zhongshan Hospital, Renji Hospital and Shanghai East Hospital. EB sits on several scientific and advisory boards of biotech and longevity hubs. Currently also affiliated with the Centre of Healthy Aging, Universität Zürich, and prev. senior attending physician of internal medicine at the University Hospital Basel. Swiss board certified as internal medicine specialist (FMH), trained in Europe, USA and China (Harvard Medical School affiliated hospitals (Mass General Hospital, Beth Israel MD, Dana Farber Institute) and Columbia University NYC; Fudan University hospitals, Shanghai and University Hospitals of Zurich and Basel (Switzerland).
Summary:
Within the last century, humans’ average lifespan has elongated by about 30 years. However, this created an exponential increase in age-related diseases, resulting in the healthspan-lifespan gap. Longevity medicine is an AI and data-driven field evolving from precision medicine, lifestyle medicine, and geroscience that aims to elongate patients’ healthy lifespan. Using biomarkers of aging, aging clocks, and continuous data monitoring, longevity physicians can bring the patient’s health from “within norms” to “optimal” or even best performance. This rapidly evolving field of medicine needs reliable and open communication between the parties involved to establish the best standards of practice to ensure efficient long-term results for the patients.
Challenge:
To achieve a profound understanding of the multifactorial interconnections of mechanisms of aging; create a variety of validated biomarkers of healthspan and ultimately use both to create druggable targets and technologies to reverse and slow down pathological aging. This should be done by physicians whose education in general and longevity medicine, as well as the ability to leverage the Large Language Models and transformers, will empower them to translate their knowledge in geroscience and longevity medicine into clinical practice.
